Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory, in good health or medically stable~* Able to understand and comply with planned study procedures~* Provide written informed consent~* Negative urine pregnancy test within 24 hours prior to vaccination (women of child-bearing potential)~Exclusion Criteria:~* Prior serious or severe reaction to influenza vaccine~* Known contraindication to either study vaccine~* Receipt of any other influenza vaccine within 180 days prior to enrollment~* Plan to receive another licensed influenza or other vaccine during the duration of this study~* Receipt of any significant new diagnosis, medication (licensed or investigational), or licensed vaccine within 30 days prior to enrollment in this study~* Underlying disease or therapeutic intervention that might adversely affect the immune response~* Plans to participate in any investigation involving an investigational product during this study.~* Pregnant, lactating or planning to become pregnant within 30 days of study vaccine.~* Any clinical or social circumstance that in the opinion of the investigator could interfere with compliance with study procedures or interfere with the interpretation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Flublok Quadrivalent Influenza Vaccine (Type: EXPERIMENTAL): Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
- Inactivated Influenza Vaccine (IIV4) (Type: ACTIVE_COMPARATOR): Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).